MORE FOR SSC: DOES IT MEAN LESS FOR OTHERS?

Volume 5, #5The Scientist March 4, 1991 MORE FOR SSC: DOES IT MEAN LESS FOR OTHERS? Author: Jeffrey Mervis Date: March 4, 1991 Every federal budget raises anew the question of whether a large increase sought for any one program will come at the expense of other programs. For scientists, the issue is best symbolized this year by the supercollider, for which the administration wants $300 million more on the road to completing the $8.25 billion facility in 1999. Administration of

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Every federal budget raises anew the question of whether a large increase sought for any one program will come at the expense of other programs. For scientists, the issue is best symbolized this year by the supercollider, for which the administration wants $300 million more on the road to completing the $8.25 billion facility in 1999.

Administration officials say they have adhered to a promise to scientists that the 54-mile-long proton-proton accelerator will not drain funds from other research projects, both within the Energy Department and throughout the government. But many analysts express disbelief at such claims, pointing to the discrepancy between the sharp rise in SSC funding and the essentially flat level of spending within high-energy physics in recent years.

"It must come out of other budgets," says the American Physical Society's Robert Park. "How could it not?"

Even Secretary of Energy James Watkins, speaking at a press briefing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies